This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by He, W. Articles by Shih, W. J. Search for Related Content PubMed PubMed Citation Articles by He, W. Articles by Shih, W. J. Social Bookmarking                         What's this?

Use of joint models to assess treatment effects on disease markers and clinical events: the ProscarTM Long-Term Efficacy and Safety Study (PLESS)

Clinical Biostatistics, Merck Research Laboratories, RY34-A316, 126 Lincoln Avenue, Merck and Co., Rahway, NJ 07065, USA; weili_he{at}merck.com

Weichung Joe Shih

Department of Biostatistics, UMDNJ School of Public Health, Piscataway, NJ 08854, USA

Clinical trials often collect longitudinal measurements of a disease marker and time to a major clinical event of the disease to assess treatment effects. It makes sense to combine the treatment effects on both the longitudinal disease marker and the time to clinical event, especially when the clinical event is also mediated through the disease marker over time. In this paper we apply a joint modeling approach in the assessment of the treatment effects in treating benign prostatic hyperplasia (BPH) for the Proscar^TM Long-Term Efficacy and Safety Study (PLESS).

Clinical Trials, Vol. 1, No. 4, 362-367 (2004)
DOI: 10.1191/1740774504cn033oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?